ALT — Altimmune, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1326190 ·
Last close
$2.61
Market Cap
$507.69M
52W High
$6.44
52W Low
$2.55
ADV30
3,927,913
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -26,229,000 | -22,825,000 | 527,212,000 | 63,008,000 | 53,004,000 |
| Mar 2026 | 0 | — | -24,244,000 | -22,563,000 | 335,630,000 | 97,601,000 | 51,643,000 |
| Dec 2025 | 26,000 | — | -28,893,000 | -27,358,000 | 279,929,000 | 43,760,000 | 55,037,000 |
| Sep 2025 | 5,000 | — | -20,859,000 | -19,014,000 | 218,447,000 | 61,236,000 | 32,846,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-71,637,000
Investing CF
$-131,062,000
Financing CF
$251,196,000
CapEx
$-22,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-672,046,000
Inventory
—
Receivables
$1,665,000
ST Investments
$233,939,000
EBIT TTM
$-88,378,000
Pretax Income TTM
$-91,081,000
Interest Exp TTM
$2,703,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$31,000
EBITDA
$-98,634,000
Free Cash Flow
$-48,786,124
Enterprise Value
$345,811,872
Total Cash
$326,280,992
Total Debt
$36,020,000
Shares Out
194,517,701
Trailing EPS
$-0.76
Book Value
$2.44
ROE
-28.9%
ROA
-17.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 41,000 | -94,489,000 | -88,093,000 | 279,929,000 | 55,037,000 | 224,892,000 | -67,535,000 |
| Dec 2024 | 20,000 | -103,172,000 | -95,059,000 | 139,306,000 | 15,798,000 | 123,508,000 | -79,848,000 |
| Dec 2023 | 426,000 | -83,510,000 | -88,447,000 | 210,640,000 | 16,541,000 | 194,099,000 | -75,810,000 |
| Dec 2022 | -68,000 | -87,740,000 | -84,713,000 | 206,928,000 | 21,635,000 | 185,293,000 | -62,586,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$2,937,000
NetIncome TTM
$-91,081,000
OpCashFlow TTM
—
Assets (Latest)
$335,630,000
Forward EPS
$-0.67
Max Pain — expiry 2026-11-20
max pain strike: $3.00 · spot: $2.61 · call oi: 3,315 · put oi: 3,268
Expected Move to 2026-11-20:
±$0.55
(21.07%) —
implied range
$2.06 –
$3.16
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EOLS | Evolus, Inc. | $510.57M | $7.73 | — |
| ARVN | ARVINAS, INC. | $492.94M | $7.64 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $492.91M | $7.46 | — |
| NGNE | Neurogene Inc. | $528.30M | $26.40 | — |
| MNPR | Monopar Therapeutics | $529.99M | $78.96 | — |
News headlines (Yahoo Finance, 1h cache)
Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise
2026-10-01 11:02 · Yahoo
Altimmune to Participate in Stifel Cardiometabolic Forum
2026-09-23 12:00 · Yahoo
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
2026-09-22 05:29 · Yahoo
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
2026-09-11 15:30 · Yahoo
Altimmune’s (ALT) Three Liver Trials Move Forward At Once
2026-09-08 02:27 · Yahoo
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
2026-09-03 12:00 · Yahoo
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ...
2026-08-12 23:03 · Yahoo
Altimmune Q2 Earnings Call Highlights
2026-08-12 14:05 · Yahoo
Altimmune, Inc. Q2 2026 Earnings Call Summary
2026-08-12 12:30 · Yahoo
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
2026-08-12 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.